MTOR and interstitial lung disease: While the mechanism of everolimus-associated pulmonary complications is not understood, some investigators have speculated that mTOR inhibition is associated with activation of the STAT1 gene, leading to increased apoptosis and injury; others theorize that a STAT3 polymorphism may increase the risk of interstitial lung disease with mTOR inhibitors [8,9].